HeartBeam to Host Third Quarter 2026 Results Conference Call on Thursday, November 12, 2026 at 4:30 p.m. Eastern Time

HeartBeam (NASDAQ: BEAT) will host its third-quarter results conference call on November 12, 2026, at 4:30 p.m. Eastern time.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SANTA CLARA, Calif.--(BUSINESS WIRE)-- HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, will hold a conference call on Thursday, November 12, 2026 at 4:30 p.m. Eastern time to discuss its results for the third quarter ended September 30, 2026. Management will be providing updates on recent achievements, including the ALIGN-ACS pilot study results, as well as upcoming milestones for the Heart Attack Detection program. A press release detailing the third quarter results will be issued prior to the call.

HeartBeam Executive Chairman Richard Ferrari, President and Founder Branislav Vajdic, Ph.D., and Chief Financial Officer Timothy Cruickshank will host the conference call, followed by a question-and-answer period.

The conference call will be accompanied by a presentation, which can be viewed during the webcast or accessed following the call via the investor relations section of the Company’s website here.

To access the call, please use the following information:

Date:	Thursday, November 12, 2026
Time:	4:30 p.m. Eastern time (1:30 p.m. Pacific time)
Dial-in:	1-877-704-4453
International Dial-in:	1-201-389-0920
Conference Code:	13763268
Webcast:	https://viavid.webcasts.com/starthere.jsp?ei=1779198&tp_key=0e699c3be5

A telephone replay will be available approximately three hours after the call and will run through November 26, 2026, by dialing 1-844-512-2921 from the U.S. and Canada, or 1-412-317-6671 from international locations, and entering replay pin number: 13763268. The replay can also be viewed through the webcast link above and the presentation utilized during the call will be available in the Company’s investor relations section here.

About HeartBeam, Inc.

HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company has developed the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-Lead ECG synthesis software received FDA clearance for arrhythmia assessment in December 2025¹. The technology is currently being studied for heart attack assessment and is considered investigational in that indication. The Company holds over 25 issued patents related to technology enablement. For additional information, visit HeartBeam.com.

¹Cleared Indications for Use

The HeartBeam System with 12-Lead ECG synthesis software is FDA cleared for arrhythmia assessment only. The technology’s use for heart attack assessment is investigational and not FDA cleared. For full details on the intended use of the HeartBeam technology, refer to the Company’s Cleared Indications for Use and full instructions at https://www.heartbeam.com/indications.

MKT-173 v0

View source version on businesswire.com: https://www.businesswire.com/news/home/20261103699541/en/

Media Contact:
media@heartbeam.com

Investor Relations Contact:
Chris Tyson
Executive Vice President
MZ North America
Direct: 949-491-8235
BEAT@mzgroup.us
www.mzgroup.us

Source: HeartBeam, Inc.

Key Terms

ecg medical

An ECG (electrocardiogram) records the heart’s electrical activity through small sensors on the skin and produces a waveform that shows heart rate, rhythm and signs of stress or damage—think of it as a seismograph for the heart’s electrical signals. Investors care because ECGs are central to diagnosing and monitoring cardiac safety in clinical trials, required for regulatory approval of many drugs and devices, and drive demand for related medical equipment and services.

non-coplanar technical

Not lying in the same geometric plane; points, lines, or paths are non-coplanar when they cannot all be contained on a single flat surface. For investors, the term matters when it describes how a product, device, or process operates—for example, medical devices or antenna arrays that use non-coplanar arrangements can reach targets or cover space differently, affecting design complexity, manufacturing cost, and market differentiation.

fda clearance regulatory

FDA clearance is the U.S. Food and Drug Administration’s official permission to market certain medical devices or diagnostic tests after reviewing evidence that they are as safe and effective as similar products already on the market. For investors, it’s like a product passing a required safety inspection — it reduces regulatory uncertainty, speeds commercial rollout, and can directly affect sales prospects, valuation, and partnership opportunities.

investigational regulatory

A product labeled investigational is one that is still being tested and has not received official regulatory approval for general use; think of it as a prototype undergoing controlled trials to prove it works and is safe. For investors, investigational status signals higher uncertainty and potential reward because success can unlock sales and value, while failure or delays can reduce expected returns and increase development costs.